Conclusion: Mood and substance use comorbidity is prevalent among patients seeking primary care office-based buprenorphine/naloxone treatment. The findings support the need for clinicians to assess and address these conditions. (Source: Drug and Alcohol Dependence)
MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.
